Proteins and Peptides: Strategies for Delivery to and Across the Skin

Benson, Heather A. E.; Namjoshi, Sarika

doi:10.1002/jps.21277

Cited by 111 publications

(61 citation statements)

References 138 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MNs provide a direct pathway for drugs to access the viable dermis, allowing for a painless DD that by-passes the SC (Benson & Namjoshi, 2008). They also differ in shape, ranging from square, circular, flat tipped, sharp tipped, etc.…”

Section: Trends In Mn Dd Methodsmentioning

confidence: 99%

“…Methods that have been employed to solve the short comings of both TDPs and hypodermic injections are ultrasound (Yamashita et al, 1996;Han & Das, 2013;Nayak et al, in press), MNs, iontophoresis (Langkjaer, et al, 1998), electroporation, chemical enhancers and others (Yamashita et al, 1996;Yang et al, 2011). These techniques can overcome the protective SC barrier as they allow the passage of large molecular compounds such as proteins and DNA (Benson & Namjoshi, 2008;Daugimont et al, 2010;Li et al, 2013;Zhang et al, 2014a,b). MN technology, in particular, has grown over the past 15 years and can permit drugs to bypass the SC layer by the insertion of micron sized needles that create micro channels through the SC Mitragotri, 2013;Pierre & Rossetti, 2014).…”

Section: Dd Routesmentioning

confidence: 99%

“…As mentioned earlier, MNs have been proposed as an alternative delivery method to TDPs and hypodermic syringes as they have shown to overcome the various short comings previously outlined. Indeed, it has been illustrated by Benson & Namjoshi (2008) and many other researchers (Li et al, 2011b;Shah et al, 2011;Liebl & Kloth, 2012) that MN research is a promising field of research to be pursued more extensively as it can be used to overcome the skin's natural defensive barrier, the SC, in both adults and children. The rate of release of the drug depends upon the controlling membrane of the TDP (Osborne et al, 2013), and therefore ensuring a consistent drug release profile can be uncertain.…”

Section: Why Mns?mentioning

confidence: 99%

“…They have an added advantage as they can permit the administration of a larger drug dose compared to solid MNs (Benson & Namjoshi, 2008). They have also been shown to allow an increase in drug infusion rate due the fact that pressure can be applied across the length of the MN with administration.…”

Section: Hollow Mnsmentioning

confidence: 99%

“…Problems can also arise from the TDP's peeling off due to the long periods for which they are required to be applied. Several approaches have been researched to overcome the problems with TDPs and allow delivery of compounds like proteins and DNA (Benson & Namjoshi, 2008;Daugimont et al, 2010;Garland et al, 2012;Chandrasekhar et al, 2013;Katsumi et al, 2014), so that they can permeate through the skin.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Microneedles for drug delivery: trends and progress

2014

View full text Add to dashboard Cite

In recent years, there has been a surge in the research and development of microneedles (MNs), a transdermal delivery system that combines the technology of transdermal patches and hypodermic needles. The needles are in the hundreds of micron length range and therefore allow relatively little or no pain. For example, biodegradable MNs have been researched in the literature and have several advantages compared with solid or hollow MNs, as they produce non-sharp waste and can be designed to allow rapid or slow release of drugs. However, they also pose a disadvantage as successful insertion into the stratum corneum layer of the skin relies on sufficient mechanical strength of the biodegradable material. This review looks at the various technologies developed in MN research and shows the rapidly growing numbers of research papers and patent publications since the first invention of MNs (using time series statistical analysis). This provides the research and industry communities a valuable synopsis of the trends and progress being made in this field.

show abstract

Section: Trends In Mn Dd Methodsmentioning

confidence: 99%

Section: Dd Routesmentioning

confidence: 99%

Section: Why Mns?mentioning

confidence: 99%

Section: Hollow Mnsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Microneedles for drug delivery: trends and progress

2014

View full text Add to dashboard Cite

show abstract

Quantum Computational Methods and Computer‐Aided Drug Design in Transdermal Drug Delivery of Nanoparticles

Mohammed,

Lanka,

Budha

et al. 2024

Drug Delivery Systems Using Quantum Computing

View full text Add to dashboard Cite

Enhancement of Wound Healing Efficacy by Increasing the Stability and Skin‐Penetrating Property of bFGF Using 30Kc19α‐Based Fusion Protein

Lee

Kim

et al. 2021

Advanced Biology

View full text Add to dashboard Cite

involvement in tissue growth and regeneration, including wound healing. Activation of FGF receptor by bFGF stimulates intracellular signaling pathways such as phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways which are related to the mitogenic response of cells. [1] As bFGF acts on various target cells involved in wound healing, its effects on wound healing have been extensively studied. [2] bFGF promotes the migration of dermal fibroblasts, keratinocytes, and endothelial cells, into wound sites and facilitates their proliferation. [3] As a result, bFGF accelerates granulation tissue formation and angiogenesis, which results in matrix formation and remodeling. [4] In recent years, a number of clinical uses of recombinant bFGF have been reported, and these include treatment of chronic wounds, second-degree burns, pressure ulcers, and diabetic foot ulcers. [5] However, its inherent instability and rapid degradation often require frequent treatments in tandem with higher concentrations. [6] The reported half-life of recombinant bFGF is less than 10 h under normal cell culture conditions and even shorter in the living organisms, which significantly limits The instability of recombinant basic fibroblast growth factor (bFGF) is a major disadvantage for its therapeutic use and means frequent applications to cells or tissues are required for sustained effects. Originating from silkworm hemolymph, 30Kc19α is a cell-penetrating protein that also has protein stabilization properties. Herein, it is investigated whether fusing 30Kc19α to bFGF can enhance the stability and skin penetration properties of bFGF, which may consequently increase its therapeutic efficacy. The fusion of 30Kc19α to bFGF protein increases protein stability, as confirmed by ELISA. 30Kc19α-bFGF also retains the biological activity of bFGF as it facilitates the migration and proliferation of fibroblasts and angiogenesis of endothelial cells. It is discovered that 30Kc19α can improve the transdermal delivery of a small molecular fluorophore through the skin of hairless mice. Importantly, it increases the accumulation of bFGF and further facilitates its translocation into the skin through follicular routes. Finally, when applied to a skin wound model in vivo, 30Kc19α-bFGF penetrates the dermis layer effectively, which promotes cell proliferation, tissue granulation, angiogenesis, and tissue remodeling. Consequently, the findings suggest that 30Kc19α improves the therapeutic functionalities of bFGF, and would be useful as a protein stabilizer and/or a delivery vehicle in therapeutic applications.

show abstract

Proteins and Peptides: Strategies for Delivery to and Across the Skin

Cited by 111 publications

References 138 publications

Microneedles for drug delivery: trends and progress

Microneedles for drug delivery: trends and progress

Quantum Computational Methods and Computer‐Aided Drug Design in Transdermal Drug Delivery of Nanoparticles

Enhancement of Wound Healing Efficacy by Increasing the Stability and Skin‐Penetrating Property of bFGF Using 30Kc19α‐Based Fusion Protein

Contact Info

Product

Resources

About